Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor

Journal of Medicinal Chemistry

Volumn 53, Issue 22, 2010, Pages 8080-8088

  Geldenhuys, Werner J ^a   Kuzenko, Stephanie R ^b   Simmons, Mark A ^a,b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Northeast Ohio Medical University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; NEUROKININ 3 RECEPTOR; NEUROKININ 3 RECEPTOR AGONIST; QUINOLINE; SENKTIDE; TALNETANT;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; COMPARATIVE MOLECULAR FIELD ANALYSIS; CONTROLLED STUDY; DATA BASE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; LIGAND BINDING; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; VIRTUAL SCREENING;

ANIMALS; BINDING, COMPETITIVE; CALCIUM SIGNALING; CHO CELLS; CRICETINAE; CRICETULUS; DATABASES, FACTUAL; HUMANS; LIGANDS; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINOLINES; RADIOLIGAND ASSAY; RECEPTORS, NEUROKININ-3; RECEPTORS, OPIOID;

EID: 78649518779     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1010012     Document Type: Article

References (14)

1. Spooren, W.; Riemer, C.; Meltzer, H. Opinion: NK3 receptor antagonists: the next generation of antipsychotics? Nature Rev. Drug. Discovery 2005, 4, 967-975
2. Regoli, D.; Boudon, A.; Fauchere, J. L. Receptors and antagonists for substance P and related peptides Pharm. Rev. 1994, 46, 551-598
3. Meltzer, H. Y.; Stahl, S. M. The dopamine hypothesis of schizophrenia: a review Schizophr. Bull. 1976, 2, 19-76
4. Meltzer, H. Y.; Arvanitis, L.; Bauer, D.; Rein, W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder Am. J. Psychiatry 2004, 161, 975-984
5. Sarau, H. M.; Griswold, D. E.; Potts, W.; Foley, J. J.; Schmidt, D. B.; Webb, E. F.; Martin, L. D.; Brawner, M. E.; Elshourbagy, N. A.; Medhurst, A. D.; Giardina, G. A.; Hay, D. W. Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist J. Pharmacol. Exp. Ther. 1997, 281, 1303-1311
6. Giardina, G. A.; Raveglia, L. F.; Grugni, M.; Sarau, H. M.; Farina, C.; Medhurst, A. D.; Graziani, D.; Schmidt, D. B.; Rigolio, R.; Luttmann, M.; Cavagnera, S.; Foley, J. J.; Vecchietti, V.; Hay, D. W. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)- N -(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4- carboxamide (SB 223412) J. Med. Chem. 1999, 42, 1053-1065
7. Agarwal, A.; Pearson, P. P.; Taylor, E. W.; Li, H. B.; Dahlgren, T.; Herslöf, M.; Yang, Y.; Lambert, G.; Nelson, D. L.; Regan, J. W.; Martin, A. R. Three-dimensional quantitative structure-activity relationships of 5-HT receptor binding data for tetrahydropyridinylindole derivatives: a comparison of the Hansch and CoMFA methods J. Med. Chem. 1993, 36, 4006-4014
8. Tropsha, A.; Golbraikh, A. Predictive QSAR modeling workflow, model applicability domains, and virtual screening Curr. Pharm. Des. 2007, 13, 3494-3504
9. Drapeau, G.; D'Orléans-Juste, P.; Dion, S.; Rhaleb, N. E.; Rouissi, N. E.; Regoli, D. Selective agonists for substance P and neurokinin receptors Neuropeptides 1987, 10, 43-54 (Pubitemid 17130244)
10. Irwin, J. J.; Shoichet, B. K. ZINC-A Free Database of Commercially Available Compounds for Virtual Screening J. Chem. Inf. Model. 2005, 45, 177-182
11. Smith, P. W.; Wyman, P. A.; Lovell, P.; Goodacre, C.; Serafinowska, H. T.; Vong, A.; Harrington, F.; Flynn, S.; Bradley, D. M.; Porter, R.; Coggon, S.; Murkitt, G.; Searle, K.; Thomas, D. R.; Watson, J. M.; Martin, W.; Wu, Z.; Dawson, L. A. New quinoline NK3 receptor antagonists with CNS activity Bioorg. Med. Chem. Lett. 2009, 19, 837-840
12. Bennett, V. J.; Simmons, M. A. Analysis of fluorescently-labeled substance P analogs: binding, imaging and receptor activation BMC Chem. Biol. 2001, 1 (1) 12
13. Simmons, M. A. Functional selectivity of NK1 receptor signaling: Peptide agonists can preferentially produce receptor activation or desensitization J. Pharmacol. Exp. Ther. 2006, 319, 907-913
14. Perrine, S. A.; Beard, D. J.; Young, J.; Simmons, M. A. The role of the N-terminal and mid-region residues of substance P in regulating functional selectivity at the NK1 receptor Eur. J. Pharmacol. 2008, 592, 1-6